semaglutide elisa fda cleared ivd Exciting news to start the year! We're pleased to announce our DCP submission for will take place on February 13th, 2026. Semaglutide is a transformative therapy for adults with type 2… Higher dose semaglutide gets fast

Restarting the treatment without consulting a healthcare provider could also trigger serious gastrointestinal side effects

Some patients ask whether breaking their weekly dose into smaller injections might offer benefits, but the evidence and clinical practice suggest your prescribed dosing schedule is designed for maximum safety and effectiveness

Their signs may include difficulty breathing, swelling of the face or neck, severe pain, vomiting, fever, and yellowing of the skin or eyes [25]

Retatrutide Clinical Trial Results: The Data Phase 3 TRIUMPH-4 Trial (December 2025) The TRIUMPH-4 Phase 3 study enrolled 445 participants with obesity or overweight who also had knee osteoarthritis